This company listing is no longer active
MTCR Stock Overview
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Metacrine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$0.59 |
| 52 Week Low | US$0.30 |
| Beta | -0.74 |
| 1 Month Change | 3.82% |
| 3 Month Change | 1.60% |
| 1 Year Change | 23.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.06% |
Recent News & Updates
Recent updates
Equillium acquires Metacrine to extend cash runway through 2024
Sep 06Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform
Jun 14Metacrine completes enrollment in mid-stage NASH trial
Jun 02Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH
Jan 05What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?
Dec 16
Metacrine reports Q3 results
Nov 12Shareholder Returns
| MTCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -2.5% | -3.2% |
| 1Y | 23.7% | -3.7% | 19.3% |
Return vs Industry: MTCR exceeded the US Biotechs industry which returned 13.8% over the past year.
Return vs Market: MTCR exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| MTCR volatility | |
|---|---|
| MTCR Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MTCR has not had significant price volatility in the past 3 months.
Volatility Over Time: MTCR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Dave Maggio | www.metacrine.com |
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc. Fundamentals Summary
| MTCR fundamental statistics | |
|---|---|
| Market cap | US$25.48m |
| Earnings (TTM) | -US$38.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs MTCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$19.49m |
| Gross Profit | -US$19.49m |
| Other Expenses | US$18.70m |
| Earnings | -US$38.19m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 37.2% |
How did MTCR perform over the long term?
See historical performance and comparison